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The potential for genome-wide association studies to relate phenotypes to speciﬁc genetic variation is greatly
increased when data can be combined or compared across multiple studies. To facilitate replication and validation
across studies, RTI International (Research Triangle Park, North Carolina) and the National Human Genome
Research Institute (Bethesda, Maryland) are collaborating on the consensus measures for Phenotypes and eX-
posures (PhenX) project. The goal of PhenX is to identify 15 high-priority, well-established, and broadly applicable
measures for each of 21 research domains. PhenX measures are selected by working groups of domain experts
using a consensus process that includes input from the scientiﬁc community. The selected measures are then
made freely available to the scientiﬁc community via the PhenX Toolkit. Thus, the PhenX Toolkit provides the
research community with a core set of high-quality, well-established, low-burden measures intended for use in
large-scale genomic studies. PhenX measures will have the most impact when included at the experimental design
stage. The PhenX Toolkit also includes links to standards and resources in an effort to facilitate data harmonization
to legacy data. Broad acceptance and use of PhenX measures will promote cross-study comparisons to increase
statistical power for identifying and replicating variants associated with complex diseases and with gene-gene and
gene-environment interactions.
environmental exposure; epidemiologic methods; genetic research; genetics; genome-wide association study;
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Abbreviations: DataSHaPER, Data Schema and Harmonization Platform for Epidemiological Research; dbGaP, database of
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sensus measures for Phenotypes and eXposures; P
3G, Public Population Project in Genomics.
Editor’s note: An invited commentary on this article ap-
pears on page 261, and the authors’ response appears on
page 265.
Genetics and the etiology of common complex
diseases
The incorporation of genomics data into population-
based studies has led to the emergence of genome-wide
association studies and a revolution in theway that scientists
think about genetics and the etiology of common, complex
diseases (1). Because of the rapid progress in genomic tech-
nology, investigators can now analyze hundreds of thou-
sands of genetic polymorphisms (2, 3) against an array of
disease phenotypes to identify associations. Genome-wide
association studies have the potential to complement re-
search focused on biochemical pathways and/or regulatory
cascades and thus inspire new hypotheses (4). Increased
understanding of disease etiology and mechanisms will fa-
cilitate development of interventions, such as novel prophy-
lactic or therapeutic agents.
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studies have identiﬁed a large number of associations be-
tween chromosomal loci and complex human diseases (5),
to date, most of these studies have had few measures in
common (6–8). It is important to compare ﬁndings across
studies to validate results and to detect relatively weak sta-
tistical associations that are commonly found when multiple
genetic polymorphisms make small contributions to com-
mon disorders. Moreover, there are environmental expo-
sures that can have important ramiﬁcations. These include
the effects of environmental factors, including ambient
environment, personal behaviors, and treatments that can
inﬂuence susceptibility, presentation, and progression of
disease. Several groups of investigators have successfully
expanded study populations by incorporating extracted
metadata from complementary studies (9, 10). For some
diseases, such as diabetes and Crohn’s disease, pooling of
multiple genome-wide association studies by meta-analysis
has led to the discovery of new gene associations (11–13).
However, standard measures could greatly simplify the
task of combining studies and validating ﬁndings. Over
time, the use of standard measures should make it possible
to build larger populations for cross-study analysis, thus pro-
viding increased statistical power and the ability to detect
moderate associations and gene-gene and gene-environment
interactions.
The consensus measures for Phenotypes and eXposures
(PhenX) Toolkit is designed to provide a core set of well-
established, low-burden, high-quality measures for use in
large-scale genomic studies. In this report, we describe the
rationale and development of the PhenX Toolkit and high-
light collaborations and harmonization efforts.
The case for standard measures
There are compelling reasons to promote the use of stan-
dard (common) measures for genome-wide association
studies and other large-scale genomic research efforts.
 Many common complex diseases share similar underlying
risk factors, such as smoking and dietary intake (14), and
seemingly disparate studies may collect this information
using different methods. Standard phenotypic and envi-
ronmental exposure measures would facilitate combining
data from a wide range of studies.
 Initial ﬁndings from genome-wide association studies
need to be replicated in follow-on studies (15). Standard
measures would allow for direct comparisons of data col-
lected in studies of different populations to validate initial
ﬁndings.
 Increasedstatisticalpowercouldbeachievedbycombining
studies, and this would facilitate the identiﬁcation and ver-
iﬁcation of relatively weak associations and of more com-
plex relations, such as gene-gene and gene-environment
interactions (16).
 A readily accessible source of standard measures and as-
sociated protocols will help investigators expand studies
to include measures that are outside of their primary re-
search focus.
RESULTS
PhenX—the project
The PhenX project is led by RTI International (Research
Triangle Park, North Carolina) and isfundedby the National
Human Genome Research Institute (Bethesda, Maryland) at
the National Institutes of Health (NIH). The goal of PhenX
is to identify and catalog 15 high-quality, low-burden, well-
established measures and accompanying standard protocols
for each of 21 research domains. The PhenX measures are
available to the scientiﬁc community via a Web-based tool-
kit (https://www.phenxtoolkit.org/).
PhenX—the process
The PhenX Steering Committee is composed of 12 sci-
entists with a range of expertise in epidemiology, biosta-
tistics, and genomics research who provide guidance
throughout the project. The Steering Committee originally
selected and deﬁned 20 research domains that are the focus
of the project (Table 1). Through collaboration with the
Ofﬁce of Behavioral and Social Science Research at the
NIH, an additional Social Environments domain was added
to the PhenX project. A PhenX domain is a ﬁeld of research
with a unifying theme and easily enumerated quantitative
and qualitative measures. Domains include Demographics,
Table 1. Research domains delineated in the PhenX Project
a
Alcohol, Tobacco and Other Substances
Anthropometrics
Cancer
Cardiovascular
Demographics
Diabetes
Environmental Exposures
Gastrointestinal
Infectious Diseases and Immunity
Neurology
Nutrition and Dietary Supplements
Ocular
Oral Health
Physical Activity and Physical Fitness
Psychiatric
Psychosocial
Reproductive Health
Respiratory
Skin, Bone, Muscle and Joint
Social Environments
Speech and Hearing
Abbreviation: PhenX, consensus measures for Phenotypes and
eXposures.
a Developed by RTI International (Research Triangle Park, North
Carolina) and the National Human Genome Research Institute
(Bethesda, Maryland).
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testinal),complexdiseases(e.g.,Cancer,Cardiovascular),and
lifestyle factors (e.g., Alcohol, Tobacco and Other Sub-
stances; Physical Activity and Physical Fitness). Liaisons
from the NIH institutes and centers participate in PhenX
activities, including nominating Steering Committee and
working group members, and are invited to participate in all
Steering Committee and working group meetings. The liai-
sons exchange relevant information with their institutes and
centers, help ensure that PhenX is coordinated with related
NIH initiatives, and provide additional content expertise.
To address each PhenX research domain, aworking group
of domain experts is assembled. The working groups are
composed of 6–9 domain experts from academic and gov-
ernment institutions. Working group members are carefully
selected to include a balance of members with domain exper-
tise and experience in epidemiology and genomics research.
Each working group member commits to participating in the
consensus process, which typically takes 7–9 months and
includes 1 in-person meeting and 4–6 conference calls.
The working group chairs play a key role, leading the work-
ing group throughout the consensus-based process. Working
group participants are recognized on the project portal
(https://www.phenx.org/). The working groups convene and
use a consensus-based process to select 15 measures to be
included in the PhenX Toolkit. Limiting the number of mea-
sures to 15 per domain ensures that the Toolkit includes
only the highest-priority, well-established measures and also
keeps the Toolkit a manageable size.
The PhenX Toolkit is designed primarily for investigators
who wish to expand their disease-speciﬁc studies into other
areas and who are unlikely to have sufﬁcient resources to
add more than a few measures from additional research
domains that are outside their primary focus. The Toolkit
provides a variety of measures; it is up to investigators to
decide which PhenX measures (and how many) they want to
incorporate into their overall study design. The overall pro-
cess of selecting PhenX measures is outlined in Figure 1.
A major concern in any genomics-based study is ensuring
accurate assessment of the phenotypes and exposures of
interest. If the data used for the analyses do not reliably
and accurately reﬂect the phenotypes or exposures, then
the associations will not be valid. It is expected that inves-
tigators will almost certainly use multiple, more detailed,
and potentially higher burden measures to assess their pri-
mary research interest but will use PhenX measures to ex-
pand their study to include measures from other research
domains.
The Steering Committee developed the following criteria
to guide the working groups in their deliberations:
 Working groups should select well-established measures.
Well-established measures may have been used over time
and/or come from highly regarded sources. The purpose
of PhenX is not to develop new measures but to recom-
mend measures that have been used successfully.
 The working group should select measures and accompa-
nying protocols for acquiring the measures that can be
used by scientists who do not have expertise in that par-
ticular domain.
 Measures are assessed with regard to burden for both
study participants and investigators. The working groups
are advised to select measures of relatively low burden to
both investigators and participants. The working groups
are asked to consider the time required to administer the
protocol, the equipment and skills required, and the over-
all cost and complexity of data collection and analysis.
A limited number of higher-burden measures may be in-
cluded.
 Working groups should select measures that are expected
to be relevant for at least the next few years.
 Working groups are encouraged to select protocols that
are broadly applicable to a variety of populations. A sin-
gle PhenX measure may have multiple context-dependent
protocols to accommodate life-stage and gender variations.
Figure 1. Consensus process used in the consensus measures
for Phenotypes and eXposures (PhenX) project. SC, Steering Com-
mittee; WG, Working Group.
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for cultural differences’ affecting the measures and take
that into consideration when selecting speciﬁc protocols.
 Although the primary focus of PhenX is research in US
populations, international measures and standards may
also be considered. Scientists from other countries are
encouraged to use the PhenX Toolkit.
The working groups review and discuss many measures
pertinent to their respective domains and select preliminary
measures (up to 25) for outreach to the broader scientiﬁc
community (Figure 1). This outreach effort seeks to engage
additional experts from the scientiﬁc community to review
and comment on these preliminary measures. The working
groups then consider this input in their ﬁnal deliberations.
Deciding on the measures to be included in the PhenX
Toolkit is a difﬁcult task, and each working group has to
balance the criteria for selection put forth by the Steering
Committee. If a measure is highly burdensome or is too
cutting-edge to be suitable for the Toolkit but the working
groupthinks it ishighlyrelevantto theresearchdomain,then
the working group may decide to include it in the Supple-
mental Information section of the Toolkit. The supplemental
information may include gold-standard, high-burden mea-
sures and/or preliminary measures that were ultimately not
selected for inclusion in the Toolkit. Other information that
the working group agrees may be of value to the user may
also be included. Thus, the supplemental information gives
the PhenX Toolkit user additional access to the expertise and
guidance of the working groups.
PhenX—the Toolkit
The PhenX Toolkit presents the measures and protocols
selected by the working groups (https://www.phenxtoolkit.
org/). Users can search or browse the Toolkit, selecting
measures of interest by adding them to a cart. From the cart,
the user can request reports that provide the information
needed to collect data on the measures. The Toolkit provides
a description of the measure, detailed protocols associated
with the measure, and other related information: for exam-
ple, rationale for selection, equipment and training required,
and references. The Steering Committee envisioned the
ﬁrst few domains as building blocks for the entire PhenX
Toolkit. Thus, Demographics, Anthropometrics, and Alco-
hol, Tobacco and Other Substances were selected as the ﬁrst
3 domains to be addressed by working groups. With this
approach, subsequent working groups, such as the Cancer
or Diabetes working group, can review measures already in
the Toolkit and then decide whether they are sufﬁcient for
their research domain. Setup of the initial 21 domains was
completed near the end of 2010, and the selected measures
are all available in the PhenX Toolkit.
Because the PhenX Toolkit includes detailed protocols
for obtaining data on the measures, Toolkit users can review
and assess whether or not a speciﬁc protocol is suitable for
their study. The expectation is that researchers who visit the
Toolkit site will be able to identify some PhenX measures
that are suitable for their study population and their avail-
able resources. Figure 2 presents a screen shot of the home
page of the PhenX Toolkit; a general summary of the PhenX
Toolkit is shown in Table 2 (17).
Visitors to the PhenX Toolkit site can browse by research
domain or search using keywords. PhenX Toolkit users can
select measures and save them in a cart. Users can easily add
to or remove measures from their cart as they decide which
PhenX measures would be most helpful for their study. The
PhenX Toolkit provides a brief description of each measure,
its purpose and rationale for inclusion, standardized proto-
cols for collecting data on the measure, supporting infor-
mation, and references. The PhenX Toolkit describes the
requirements for each measure, including details about the
personnel and equipment needed to collect data on the mea-
sures. Users can request a report that provides the details of
their selections, thus facilitating incorporation of these mea-
sures into the study design. In addition, the Toolkit alerts
users if additional measures (essential data) are needed to
interpret a selected measure. For example, if Toolkit users
select ‘‘blood pressure,’’ the users are prompted to also add
‘‘current age,’’ ‘‘gender,’’ ‘‘race,’’ and ‘‘ethnicity’’ to their
cart (i.e., a speciﬁc collection of measures). After following
a simple registration process, registered Toolkit users can
save multiple carts and can share their carts with other reg-
istered users via a Toolkit network. This allows investigators
who are planning different studies (or expanding an existing
study) to work together to include a common set of PhenX
measures for future analyses. A data collection form that
will help investigators collect the data associated with
PhenX measures is currently in development. The data col-
lection form will also make it easy for investigators to in-
tegrate PhenX measures into their primary study design.
DISCUSSION
The use of standard measures for analysis
Once an individual has been genotyped, that genotype can
potentially be related to any trait, not just the primary phe-
notype in the original study (14). Because many of the target
(primary) phenotypes of research studies are complex con-
ditions or disorders, data are commonly collected on multi-
ple risk factors and comorbid conditions. This opens the
door to cross-study analyses of not only the primary pheno-
types but also secondary phenotypes (18–21).
Although reports have clearly demonstrated the value of
integrating data across related studies and even across disci-
plines (22), most genome-wide association studies to date
have focused on a speciﬁc disease or trait.The PhenXToolkit
is designed to aid investigators who are interested in expand-
ing their study to include measures that are outside of their
primaryareaofexpertise.Forexample,aninvestigatorwhois
planning a neurology study may choose PhenX measures
in the Nutrition and Dietary Supplements, Cancer, and Res-
piratory domains in addition to PhenX Neurology measures.
It is also worth noting that some conditions or diseases
m a yb ea s s o c i a t e dw i t ht h es a me phenotype, such as obe-
sity with cardiovascular disease and diabetes. Perhaps even
more important, expanding genomics-based studies to in-
clude phenotypes outside of the primaryresearchinterest is
essential to understanding pleiotropic genetic effects (23).
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PhenX measures, new relations between seemingly unre-
lated disciplines are likely to be uncovered. Figure 3 illus-
trates the incorporation of PhenX measures into individual
studies and the resulting ability to combine data from mul-
tiple studies.
To achieve data interoperability, the adoption of standard
data formats and vocabularies is essential (24). The incor-
poration of PhenX measures into individual studies at the
experimental design stage and/or prior to collecting the data
will make it possible to easily combine data from multiple,
largely unrelated studies. Combining studies generates in-
creased statistical power and the ability to detect both more
subtle and more complex—and, perhaps, unexpected—gene
associations.
The PhenX Toolkit
Limitations. The PhenX Toolkit is designed to help in-
vestigators effectively expand their studies, but there are
Figure 2. Home page of the consensus measures for Phenotypes and eXposures (PhenX) Toolkit.
The PhenX Toolkit 257
Am J Epidemiol. 2011;174(3):253–260limitations. Each working group is asked to balance multi-
ple criteria for selecting measures (deﬁned by the Steering
Committee) as they decide what measures to include in the
Toolkit. Current limitations are: 1) the Toolkit does not
necessarily include the gold standard for each research do-
main, as these measures are often quite burdensome to ad-
minister; 2) promising but relatively new measures are not
included in the Toolkit because they are not yet well estab-
lished; and 3) established protocols are not modiﬁed (al-
though some working groups indicated that this could be
beneﬁcial).
Collaborations and harmonization. The PhenX investiga-
tors are currently collaborating with administrators of the
database of Genotypes and Phenotypes (dbGaP) (8) (http://
www.ncbi.nlm.nih.gov/gap/), the Public Population Project
in Genomics (P
3G) (25) (http://www.p3g.org/), the Data
Schema and Harmonization Platform for Epidemiological
Research (DataSHaPER) (26) (http://www.datashaper.org/),
and the National Library of Medicine (http://www.nlm.nih.
gov/). This work is focused on developing a consistent rule
set for mapping PhenX measures to dbGaP study variables
and DataSHaPER measures and variables. The plan is to
highlight PhenX measures in dbGaP and DataSHaPER.
The value of this approach is that investigators who visit
the dbGaP or DataSHaPER site will be able to readily iden-
tify PhenX measures in these resources, thus facilitating
data-sharinganddataharmonization.In addition, researchers
may be able to identify opportunities to extend studies to
include data and samples associated with P
3G bioreposito-
ries. The PhenX investigators are working collaboratively
with the National Library of Medicine to ensure that PhenX
is aligned with NIH bioinformatics efforts such as Logical
Observation Identiﬁers Names and Codes (27, 28). They are
also collaborating with the Electronic Medical Records and
Genomics consortium (https://www.mc.vanderbilt.edu/) to
facilitate sharing of data captured in electronic medical
records.
The use of PhenX measures will facilitate downstream
harmonization and meta-analysis. The compelling need to
combine studies and to take advantage of legacy data has
led to efforts to harmonize similar data elements. Harmoniza-
tion efforts such as P
3G, DataSHaPER, and the Gene Envi-
ronment Association Studies (GENEVA) consortium are
currently under way. DataSHaPER is focused on developing
tools for retrospective data harmonization (26). The GENEVA
consortium has established a uniﬁed framework for geno-
typing, data quality control, analysis, and interpretation
(14). Harmonization methods that make it possible to com-
pare or combine related data types for meta-analysis have
p r o v e nt ob ev e r ye f f e c t i v e( 2 9 )a n dw i l la l w a y sb ea n
option.
Bioinformatics. As a result of supplemental funding pro-
vided under the American Recovery and Reinvestment Act
of 2009 (Public Law 111–5), PhenX is extending the Tool-
kit’s browse and search capabilities to better reﬂect the in-
terrelatedness of measures across the research domains and
collected statistics from Toolkit users (such as ‘‘top 10’’
measures). Measures are currently organized into various
groups or collections to allow investigators to browse the
Toolkit from a variety of perspectives. For example, in
addition to being able to browse measures by ‘‘research
domain,’’ users may identify measures of interest by
browsing collections of measures such as ‘‘risk factors’’ or
‘‘life stages.’’ This approach could be extended to help Tool-
kit users assess complex diseases and conditions. For exam-
ple, investigators could come to the Toolkit and ﬁnd
measures associated with Sjo ¨gren’s syndrome or metabolic
syndrome even though the measures may have been selected
by several different working groups. The Smart Query tool
helps Toolkit users ﬁnd measures using keywords or con-
cepts and traverses the entire Toolkit to provide relevant
measures for consideration. A data collection form and
a data dictionary are being developed for the Toolkit that
will make it easier for investigators to collect and analyze
the data associated with PhenX measures. Also in develop-
ment is a comprehensive bioinformatics mapping document
Figure3. Beneﬁtsof usingmeasuresfrom theconsensusmeasures
for Phenotypes and eXposures (PhenX) Toolkit. CVD, cardiovascular
disease.
Table 2. Deﬁning the PhenX Toolkit
a
What the PhenX
Toolkit Is
What the PhenX
Toolkit Is Not
A catalog of recommended
measures for inclusion in
new studies or when
expanding existing studies
A database that allows
researchers to browse,
search, and select
measures
Cross-referenced to Cancer
Biomedical Informatics Grid
common data elements
Freely available to the
scientiﬁc community
Not a new set of
standards
Not a new ontology
of phenotypes
Not a data repository
Not a biobank
Not restrictive
Not a proprietary
resource
Abbreviation: PhenX, consensus measures for Phenotypes and
eXposures.
a Developed by RTI International (Research Triangle Park, North
Carolina) and the National Human Genome Research Institute
(Bethesda, Maryland).
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standards.
Future directions. We are developing a strategy to raise
the visibility of the Toolkit and promote its use by epidemi-
ologists and other investigators. Based on Toolkit user feed-
back, we expect to continue to update the functionality of
the Toolkit. We plan to establish a process for updating
Toolkit content. As complementary and related research
efforts mature, some of these measures may be incorporated
into the PhenX Toolkit. For example, the Patient-Reported
Outcomes Measurement System (http://www.nihpromis.
org/) is developing new instruments for effectively capturing
patient-provided information, and the NIH Toolbox (http://
www.nihtoolbox.org/) is focused on developing new proto-
cols for neurologic and behavioral assessments.
We also envision that the results of our current collabo-
rative efforts will facilitate the mapping and highlighting
of PhenX measures in additional data repositories and re-
sources. The PhenX team will continue to welcome addi-
tional opportunities to collaborate.
Summary
The PhenX Toolkit provides the research community with
a core set of high-quality, well-established, low-burden
measures intended for use in genome-wide association stud-
ies and other population-based studies. More speciﬁcally,
the PhenX Toolkit will make it easy for researchers to
effectively expand a study to include standard measures
outside of their primary research focus. Broad acceptance
and use of PhenX measures will promote cross-study com-
parisons to increase statistical power for identifying and
replicating variants associated with complex diseases and
with gene-gene and gene-environment interactions. The
hope is that the PhenX Toolkit will be widely adopted by
the scientiﬁc community, fostering a new era of cooperation
and collaboration and facilitating cross-study, transdisci-
plinary, and translational research.
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